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Abstract 
Health care expenditure growth is affected by important unobserved common shocks 
such as technological innovation, changes in sociological factors, shifts in preferences and the 
epidemiology of diseases. While common factors impact in principle all countries, their effect 
is likely to differ across countries. To allow for unobserved heterogeneity in the effects of 
common shocks, we estimate a panel data model of health care expenditure growth in 34 OECD 
countries over the years 1980 to 2012 where the usual fixed or random effects are replaced by 
a multifactor error structure. We address model uncertainty with Bayesian Model Averaging, 
to identify a small set of important expenditure drivers from 43 potential candidates.  We 
establish 16 significant drivers of healthcare expenditure growth, including growth in GDP per 
capita and in insurance premiums, changes in financing arrangements and some institutional 
characteristics, expenditures on pharmaceuticals, population aging, costs of health 
administration, and inpatient care. Our approach allows us to derive estimates that are less 
subject to bias than in previous analyses, and provide robust evidence to policy makers on the 
drivers that were most strongly associated with the growth in health care expenditures over the 
past 32 years.   
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1. Introduction 
In empirical country-level models of health care expenditure (HCE) growth great 
importance is placed on common factors.  These are exogenous influences on expenditure 
growth that are unobserved but affect all countries in specific time periods.  The most 
prominent common factor is technological change, in particular advances in medical care 
technology.  In addition, changes in sociological factors, lifestyle, epidemiology of diseases, 
shifts in preferences of patients, and the global economic situation are potentially important 
drivers of expenditure growth that are absorbed in the common factor if they are unobserved. 
Some studies have used proxies for technological change such as R&D expenditures in all 
sectors or in health care (Okunade and Murthy, 2002), surgical procedures (Baker and Wheeler, 
1998), the number of specific medical equipment (Weil, 1994), neonatal survival, or life 
expectancy and infant mortality (Dreger and Reimers, 2005).  This is problematic because 
proxies are imperfect and results vary across studies.  Therefore most studies still adopt variants 
of the ‘residual approach’ (Chernew and Newhouse, 2011, and references in table 1.3), which 
was pioneered for the economy in general by Solow (1957).  It measures time-varying 
observable cost drivers, and generally attributes the rest of spending growth to technology and 
other common factors.  They are captured by the residual for unobserved factors that are 
assumed to differ across countries, and by a time index (Gerdtham and Löthgren, 2000), time-
specific intercepts (Di Matteo and Di Matteo, 1998) or year fixed effects (Smith et al., 2009) 
for factors that are assumed common.   
Panel data models of HCE growth with year fixed effects rest on the assumption that 
the association between unobserved common factors and expenditure growth is homogenous.  
This implies that the impact of common shocks is assumed to be the same in all countries, and 
that there is no association between the residual, the unobserved common factors and observed 
determinants of expenditure growth.  These assumptions have been challenged by research 
demonstrating that countries differ quite markedly in the rate by which they adopt technological 
innovations in health care, although knowledge innovations are in principle accessible to all, 
i.e. constitute common shocks (Greenhalgh et al., 2008).  For example, in the adoption of 
innovation in cardiac procedures countries can be classified into three patterns: early start and 
fast adoption; late start/fast adoption; and late start/slow adoption (Lyttkens, 2001).  While the 
literature on HCE growth is extensive, there has not been much progress with incorporating 
these findings.  
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Our study allows for heterogeneity in the impact of common shocks, to identify the 
main drivers of HCE growth in OECD countries over the period 1980 and 2012.  We estimate 
a panel data model of HCE growth where the usual fixed or random effects are replaced by a 
multifactor error structure as proposed by Pesaran (2006).  The factor structure synthesizes the 
effects of shocks that may hit health spending in different time periods.  While those common 
factors affect in principle all countries, our model allows for their differing impact on growth 
across countries.  The theoretical literature has shown that a multifactor error structure leads to 
estimates that are less subject to bias.  Main objective of our study is to generate unbiased 
estimates of the most important drivers of HCE growth.  What constitutes ‘most important’ has 
been subject to some debate, because analysis of HCE growth is affected by high model 
uncertainty.  While there is now an impressive amount of evidence on the individual 
importance of determinants (Chernew and Newhouse, 2011), there is little guidance for policy 
makers where to focus cost-containment efforts.  We use Bayesian Model Averaging (BMA) 
to address model uncertainty in HCE growth analysis.  It is a technique designed to help 
account for the uncertainty inherent in the model selection process, something which traditional 
econometric analysis often neglects. By averaging over many different competing models, 
BMA incorporates model uncertainty into conclusions about parameters and prediction.  This 
technique allows us to identify a small set of highly influential expenditure drivers from many 
potential candidates.  Our study offers two methodological contributions to the analysis of HCE 
growth, to derive results that are more accurate and informative than those from previous 
studies.  We use common factor modelling to allow for heterogeneity in the impact of common 
shocks, and BMA to address model uncertainty.  The improved results are then used to inform 
policy makers on the magnitude of impact of the most important drivers of HCE growth.   
 
2. Background 
Recently, the econometrics literature on panel data has focused on common factors that 
represent unobserved, time-varying heterogeneity that stems from omitted common variables 
or global shocks that affect each country or observational unit differently (Andrews, 2005, 
Pesaran, 2006, Bai, 2009, Peng and Forchini, 2014).  Studies are mostly motivated by 
modelling of economic growth.  It is assumed that common shocks affect output directly 
(through the total factor productivity or Solow residual), but also indirectly via the input in the 
production process (e.g. through investment decisions).  When common shocks have 
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homogeneous effects on the output, the model collapses to the usual time effect.  It is the 
heterogeneity that gives rise to a factor structure. Earlier contributions to the literature allow 
only for models with factor structure in the errors (Case, 1991, Conley, 1999) for which 
consistent estimation of the parameters can be done by maximum likelihood procedures or by 
estimation procedures based on principal components applied to the residuals (Coakley et al., 
2006).  More recently, it has been noticed that common shocks are likely to affect both the 
dependent variable and the regressors and would thus induce endogeneity requiring more 
sophisticated estimation procedures (Andrews, 2005, Pesaran, 2006).  Pesaran (2006) proposes 
estimators that are consistent when both the N and T dimensions tend to infinity.  These results 
have been extended by Bai (2009) to set-ups that allow for a more complex dependence of the 
regressors on the unknown factors and factor loadings, by Su and Jin (2012) and Huang (2012) 
to semiparametric models, and by Peng and Forchini (2014) to models for fixed T and N 
tending to infinity and less restrictive conditions. 
Common factor models have an obvious application in the analysis of HCE growth 
because of the importance of common shocks.  If all heterogeneity in the effects of common 
shocks were observable, then the problem could be solved -or at least alleviated- by a 
specification that includes interactions terms between the observable regressors and time, and 
that allows for time-varying slope coefficients, as for example proposed by Chernew and 
Newhouse (2011).  However, the literature finds that a substantial proportion of differences in 
the spread of technology, and other common shocks, is due to factors that are either 
unobservable altogether, or unobserved in the country level data that are typically used by 
studies on HCE growth (McClellan and Kessler, 1999, Lyttkens, 2001, Packer et al., 2006, 
Hashimoto et al., 2006, Greenhalgh et al., 2008).  If this is the case, then changes in unmeasured 
factors may cause the observed relationship between covariates and spending to change over 
time.  As a result, heterogeneity in the impact of latent common factors on HCE growth in 
countries introduces cross-section dependence, endogeneity and correlation between year fixed 
effects and regressors.  This may lead to inconsistent estimates and erroneous inference on the 
importance of observable drivers of expenditure growth, a problem that cannot be eliminated 
with interaction terms and time-varying slopes.  The factor structure can capture any 
contemporaneous correlation that arises from the common response of countries to such 
unanticipated events, and recognize that there is cross-country dependence in HCE, caused by 
unobservable common factors in specific time periods.   
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We use the model proposed by Pesaran (2006), because we want to allow for the 
possibility that heterogeneity in the impact of common shocks on HCE growth could -at least 
partly- be explained by observable factors.  These could relate to the organization of the health 
system, overall income level or other factors.  For example, insurance tends to shield patients 
from most of the cost of care at the margin and passively reimburses on a disaggregated, fee-
for-service basis, which gives greater encouragement to quality and cost-increasing technology 
in insurance based systems; competition between providers fosters spread of quality improving 
and cost saving medical technology; higher incomes increase demand for quality and make 
innovations more profitable to introduce.  It is even possible that certain health system traits 
do not have a great effect on spending growth in themselves, in particular if they change little 
over time; instead, their impact on spending growth predominantly arises because they are 
correlated with the common factor, and it is the interaction between the observed system trait 
and the unobserved common factor which impacts on spending.   
Two studies have applied common factor modelling to the analysis of HCE.  Baltagi 
and Moscone (2010) focus on the relation between HCE and GDP per capita, to address the 
long-standing issue of the magnitude of the income-elasticity of healthcare spending, using a 
panel of 20 OECD countries over the period 1971–2004.  They control for both cross-section 
and spatial dependence.  Heterogeneity is handled through fixed effects in a panel 
homogeneous model and through a panel heterogeneous model.  Mello-Sampayo and Sousa-
Vale (2014) analyse the relationship between HCE and type of financing in a panel of 30 OECD 
countries from 1990 to 2009. Both studies focus on the time series properties of their model, 
and analyse absolute HCE (not growth) and only include a few regressors: population aged 
over 65 years old and under 15 years old, and proportion of government expenditure on total 
expenditure; Mello-Sampayo and Sousa-Vale (2014) also include two proxies of medical 
technology.  Neither study estimates the magnitude of impact of cost drivers, the main objective 
of our study.   
Identifying determinants of expenditure growth has proven difficult because of high 
model uncertainty.  A large and varied number of potential determinants of expenditures have 
been suggested (Chernew and Newhouse, 2011), but for each study that finds evidence for a 
determinant, there is at least one other study that finds evidence against.  Even if there is 
consensus, there is uncertainty about the magnitude of its impact.  For example, nearly all 
studies uncover rising income –generally proxied by GDP per capita- as an important cost 
driver, but estimates of the income elasticity of HCEs vary (Hartwig, 2008).  Model uncertainty 
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forces researchers to ignore the uncertainty surrounding the model selection process and base 
inference on an essentially arbitrary chosen subset of regressors (Moral-Benito, 2010).  We use 
Bayesian Model Averaging (BMA) on least squares estimation as proposed by Sala-i-Martin 
et al. (2004) extended to a panel data framework to estimate all model specifications given our 
data.  We then examine whether the estimated results for any determinant are sufficiently stable 
(‘robust’) across most specifications. By doing so, we are considering not only the uncertainty 
associated with the parameter estimate conditional on a given model, but also the uncertainty 
of the parameter estimate across different models.  This approach leads us to more reliable, or 
at least more honest, conclusions regarding the significance of the estimated effect of a 
determinant (Moral-Benito, 2010).   
A recent paper by Hartwig and Sturm (2014) applies frequentist model averaging to the 
analysis of HCE growth for 33 OECD countries over the period 1970–2010.  They test a large 
number of macroeconomic and institutional determinants of HCE growth.  Results confirm 
earlier findings that GDP growth and a variable representing Baumol’s ‘cost disease’ theory 
emerge as robust and statistically significant determinants of HCE growth. Depending on 
whether or not outliers are excluded, there are six additional robust drivers: the growth in 
expenditure on health administration, the change in the share of inpatient expenditure in total 
HCE, the (lagged) government share in GDP, the change in the insurance coverage ratio, the 
growth in land traffic fatalities and the growth in the population share undergoing renal dialysis.   
3. Data 
Main data source for our study is the OECD Health Statistics (OECD, 2014), supplemented 
with institutional variables of the organisational features of healthcare systems.  These are 
binary variables, obtained from Christiansen et al. (2006) and extended to the year 2012 by us.  
In total, our study tests 43 determinants in 34 countries between 1980 and 2012.  Table 1 lists 
countries, and table 2 presents variable descriptions and summary statistics.  We broadly follow 
Hartwig and Sturm (2014) in choice of determinants, but we include additional variables that 
have been suggested in the literature.  We follow common practice and convert all level 
variables into growth rates and all proportion/share variables into first differences.   
The presence of missing values in the OECD data poses a problem. In order to expand 
the number of drivers that we can test for importance, and investigate changes in expenditures 
over a relatively long period from 1980 to 2012, we impute missing values for determinants 
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with multiple imputation (MI) (STATA, 2013). We do not impute the dependent variable but 
drop country-years with missing values, thus creating an unbalanced panel (see table 1 for 
available country-years). We only analyse determinants if less than 50% values are missing 
across country-years. MI predicts the missing data in a manner that allows for uncertainty about 
the values of the missing data, while at the same time maintaining the overall covariance 
structure of the variables. This ensures that causal inferences are not being driven by the 
randomness of a given imputation. MI adjusts the standard errors in the estimated relationship, 
to account for the fact that there is additional uncertainty relating to the imputation (Rubin, 
1987). 
MI proceeds in three steps (for details see section 4): (1) generate M imputations 
(completed data sets); (2) conduct desired analysis on each imputation separately; (3) combine 
results obtained from the second step for each completed data set into a single multiple-
imputation result (Rubin, 1987, Kenward and Carpenter, 2007, Horton and Lipsitz, 2001).  We 
use predictive mean matching using three nearest neighbours and M=50 imputed datasets, 
following White et al. (2011). This method fills in multiple variables iteratively using a 
sequence of univariate imputation methods with fully conditional specification of prediction 
equations. It accommodates arbitrary missing value patterns, and it allows us to include country 
and year dummies and utilise robust standard errors. Summary statistics for two imputed data 
sets and all imputed variables are presented in Table 3. Comparing the summary statistics of 
the imputed variables with the original ones in Table 2, we are reasonably confident that the 
imputations can be used for further analysis.      
 
4. Econometric Framework 
The innovative contributions of our study are to account for heterogeneity in the effects 
of common factors by allowing a multifactor error structure, and to address model uncertainty 
with the use of Bayesian Model Averaging. These innovations allow us to derive unbiased 
estimates on the drivers that are most strongly associated with the growth in HCE.  A panel 
data model of HCE growth with multifactor error structure (Pesaran, 2006, Bai, 2009) can be 
written as  
 , 1,..., ;      1,..., it it i ity i N t T   x   (1) 
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where yit is HCE growth in country i and time period t;  is a  vector of regressors and 
 represents the heterogeneous coefficients for the i-th country. The error term is assumed to 
have a multiple factor structure  
,it i t ite  f    (2) 
where  1 ,...,t t mtf f f  is a 1m  (m is normally unknown) vector of unobserved factors,  
 1 ,...,i i mi     is a 1m  vector of factor loadings and  is an idiosyncratic error with 
mean of zero and assumed to be uncorrelated with the regressors in itx .
1 While a conventional 
panel data model allows for common shocks, it makes the restrictive assumption that they affect 
all countries in the same way. The factor structure represents a generalization of the 
conventional error components approach in the sense that it allows for unobserved time-
specific factors to affect all countries in different ways; for example, it allows for variations in 
the rates by which countries adopt or implement new technology that becomes generally 
available in specific time periods. 
Some of the causes of unobserved heterogeneity in the effects of common shocks 
remain unobserved, and would then be absorbed in the factor loadings. Therefore, in addition, 
we allow correlation of unobserved factors tf  with observable cost drivers in itx  and adopt the 
pooled common correlated effect (PCCE) estimator proposed by Pesaran (2006). The PCCE 
estimator does not require estimating m, the number of unobserved latent factors (except to 
assume m is fixed and finite), and is valid when tf  are correlated with itx . It is desirable to 
allow for such correlation, because some determinants that lead to heterogeneity in the impact 
of unobservable common shocks are observed in empirical models of HCE growth. For 
example, the spread of medical technological change has been shown to correlate with well-
observable drivers of costs such as income per capita and the extent of insurance coverage. 
Therefore unobserved shocks can be thought of as omitted variables. Failure taking them into 
account may lead to biased estimates of 's .   
                                                          
1 The conventional panel data model with standard two-way error components, i.e. 
it i t itu e     is a special 
case of (2) by setting 2, ( ,1)i im u    , and (1, )t tf     so that i t i tf u    , with  representing an 
individual-specific time-invariant effect and  a time-specific individual-invariant effect. 
itx 1k
i
ite
iu
t
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Given the large number of potential growth determinants, there potentially exist an 
enormous amount of empirical models when the empirical researcher seeks to explore different 
combination of determinants. Suppose we have K potential determinants, we then would have 
a maximum of 2K  possible combinations of regressors, i.e. 2K  models to estimate. Let rM  (
1,2,...,2Kr  ) denote the r-th model under consideration, then rM  depends on a set of growth 
determinants, rX , and their corresponding coefficients 
r .  Let   be a vector of parameters 
that has a common interpretation in all models, i.e.   is a function of 
r  for each 1,2,...,2
Kr 
. For point estimations of  , we can take expectations of the posterior densities of the 
parameters of all models under consideration, and obtain  
2
1
( | ) ( | ) ( | , ).
K
r r
r
E p M E M

y y y  , (3) 
where the posterior probability of , i.e. ( | )rp M y , assesses the degree of support for model 
rM , and ( | , )rE My  is the posterior expectation of   under model rM . Following Leamer 
(1978), the posterior variance of  is given by  
 
2 2
2
1 1
Var( | ) ( | )Var( | , ) ( | ) ( | , ) ( | ) .
K K
r r r r
r r
p M M p M E M E
 
   y y y y y y      (4) 
The posterior variance of   incorporates not only the weighted average of estimated variances 
from each individual model, but also the weighted variances in estimates of   across different 
models. Following Sala-i-Martin et al. (2004), we apply the so-called BACE (Bayesian 
Averaging of Classical Estimates) approach. In this approach, a diffuse prior is assumed for a 
given model rM , therefore Bayesian posterior expectations of   are identical to the classical 
estimation from OLS. Then Equation (3) can be rewritten as  
                                          
2
1
ˆ( | ) ( | ) ,
K
r
r
r
E p M

y y                                   (5) 
where ˆ
r is the generic OLS estimator for   from model rM . By applying common factor 
model to our study, ˆ
r  is the PCCE estimator. 
rM

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The logic of Bayesian inference is to obtain results for every possible model given the 
data, and average them. The weights in the averaging are the posterior model probabilities. The 
logic is straightforward, but implementation can be difficult when 2K  (the number of models 
under consideration) is large. It is then practically impossible to incorporate every possible 
model in the averages as given by Equations (3) and (4). This has led to the development of 
various algorithms that do not require estimating all possible models and instead approximate 
results (Madigan, et al. 1995, George and McCulloch 1993, Geweke 1999, Clyde, et al. 1996). 
In this study we adopt the ‘stratified sampling’2 method proposed by Sala-i-Martin, et al. 
(2004). Appendix I covers Bayesian Model Averaging, and Appendix II multiple imputation 
in the context of our model. 
5. Results 
Table 4 presents results for robust regressors from Bayesian model averaging over 
common factor (CF) models in panel A. For comparison, results from fixed-effect models (with 
both individual country effects and year effects) are presented in panel B. Results for posterior 
means and posterior standard deviations conditional on inclusion are as calculated by Equation 
(3) and (4) respectively. From the posterior density we estimate the posterior probability that a 
variable’s coefficient has the same sign as its posterior mean conditional on inclusion, which 
is indicated as “Sign Certainty Probability”.  If sign certainty is above 95%, then the coefficient 
would be 10-percent significant in a two-tail test in classical terms, and we can be 90% 
confident that the variable is a robust driver of HCE.  We further report the fraction of 
specifications for which the absolute value of a determinant’s t-statistic is larger than 2.3  
Estimates of the magnitude of impact of robust determinants on HCE growth are presented for 
the CF models. This shows the % change in growth rate associated with a one within-country 
standard deviation (SD) % change of the determinant.  Results for determinants that are not 
robust are presented in figure 1.4 Sign certainty is plotted on the x-axis, and in order to allow 
interpretation as ‘Probability of determinant being positive’, the values are subtracted from 
unity for determinants with a negative posterior mean.  The fractions of significant 
specifications are plotted on the y-axis.  
                                                          
2 For technical details, please refer to Sala-I-Martin et al. (2004) and its Technical Appendix. 
3 For ease of exposition referred to as ‘significance’ in the remainder of the paper. 
4 Tables of estimates are available from the corresponding author on request. 
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We can identify 16 robust variables from the CF models.  Growth in GDP is positively 
associated with expenditure growth, confirming results from many previous study that income 
is a critical factor in determining how much nations spend on medical care (Chernew and 
Newhouse, 2011).  It consistently explains around 90% of variation in real health spending 
across countries and time (Smith et al., 2009). Empirical estimates tend to find a macro-level 
income elasticity of about 1.0 after adjusting for other factors that are correlated with GDP 
such as technology, medical prices and insurance, implying that health spending moves in 
tandem with GDP (Gerdtham and Jönsson, 2000).  More recent studies estimate elasticities of 
below one, suggesting the necessity nature of healthcare (Dreger and Reimers, 2005, Baltagi 
and Moscone, 2010).  This is confirmed by our results; a one SD % increase in GDP growth 
rate is associated with a .77% increase in HCE growth rate.  
Growth in insurance premiums for private and social insurance is positively associated 
with growth in HCE; insurance payments make up part of measured healthcare expenditures, 
and growth in premiums are likely to directly translate into HCE growth.  Impact is largest 
among all robust regressors at a 1.31% increase in HCE growth.  However, changes in the 
proportion of health expenditures funded by social and private insurance are negatively 
associated with HCE growth; i.e. countries that have re-oriented their health system towards a 
greater role of social or private insurance in financing, and by default a smaller role for public 
financing, have experienced a reduction in HCE.  According to our results, increases lead to 
.96% and .51% reductions in HCE, respectively. Woolhandler et al. (2003) have estimated that 
moving to a Canadian-style social insurance system would reduce U.S. administrative costs by 
10–15 percent of total health spending, confirming our result.  Research on the expenditures 
impact of private health insurance is conflicting, for a discussion in the context of OECD 
countries see Colombo and Tapay (2004).  On the one hand, private insurers operating in a 
competitive market may improve efficiency in administering insurance plans and enforce pressures 
on health service providers to minimise costs.  On the other hand, coverage provided by multiple 
competing insurers can be administratively costly, and market failures resulting from information 
asymmetries and moral hazard may ultimately increase costs.  Our results for private insurance 
would support the first line of arguments.  
An increase in pharmaceutical sales per capita is positively associated with healthcare 
expenditure growth. Pharmaceuticals account for almost a fifth of all health spending on 
average across OECD countries (Docteur et al., 2008), and diffusion of new drugs has been an 
important factor contributing to increased pharmaceutical expenditure and overall HCE 
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(Docteur et al., 2008, Clemente et al., 2008). However, the relationship between 
pharmaceutical spending and total health spending is a complex one, in that increased 
expenditure on pharmaceuticals to tackle diseases may be offset by reduced morbidity and need 
for costly interventions in future (Dormont et al., 2006). This is not an effect we can analyse, 
and we find the impact of pharmaceuticals to be comparably high at 0.83% increase in HCE 
growth.  An increase in the proportion of the population above 65 years is associated with an 
increase in HCE growth at 0.4%. A straightforward explanation seems to be the greater 
morbidity among the elderly population, but some have contested this based on evidence that 
the impact of age disappears once proximity to death is controlled for (Zweifel et al., 2004). 
Healthcare resource use is most intense in the few months before death, and medical expenses 
during additional life years spent in relatively good health may hardly impact on overall 
lifetime spending. The unemployment rate is negatively associated with expenditure growth, 
i.e. an increase in the unemployment rate is associated with a decrease in HCEs. 
Unemployment rises in times of financial crises, and associated reductions in tax revenue and 
increases in the social budget devoted to unemployment benefits and other social contributions 
have been found to reduce public funds for healthcare (Cylus et al., 2012, de Belvis et al., 
2012). Similarly, recessions slow the growth in wages with negative impact on private 
healthcare expenditures. Growth in public spending on education and expenditures of general 
government are positively associated with healthcare spending, indicating that spending across 
different public services is complementary rather than substitutive. Associations are 0.46% and 
0.34%, but the determinants are significant in only 88% and 53% of all specifications.  
Inpatient care discharges and acute care beds are positively associated with HCE 
growth. Most countries have made efforts to substitute inpatient care with less costly outpatient 
and daycase treatments, and our result show that countries which were more successful with 
this substitution have indeed profited from a slower growth in HCE. Reductions are associated 
with .35% and .28% reductions in HCE (at low significance for beds, however). This result is 
confirmed by previous findings (Docteur and Oxley, 2003). An increase in the costs of 
expenditures on health administration is positively associated with expenditure growth 
although the effect is small at 0.35%. In some countries, administration account for a sizable 
proportion of the health care budget. Highest costs are recorded for the USA, at around 31.0 
percent of HCE in the United States. Rates are lower in most other countries, for example just 
under 17% in Canada (Woolhandler et al., 2003). Our results confirm previous evidence 
(Hartwig and Sturm, 2014).  Inpatient expenditures is negatively associated with HCE. This is 
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a counterintuitive result that is difficult to explain, and also found by Hartwig and Sturm 
(2014), however, it is significant in less than 80% of specifications.  Tobacco consumption has 
a robust positive association with HCE, but only 46% of specifications are significant.  
A change towards, or away from, capitation remuneration and a public contract 
healthcare system are the only institutional determinants associated with a robust increase, or 
decrease, in HCE growth, however the effects are small at 0.22% and 0.05%, and less than 
90% of specifications are significant. Capitation is usually considered as cost-containing, 
which is not supported by our result. However, it has been found that there are great variations 
in the way capitation is implemented (Rice and Smith, 2001).  Public contract systems are 
generally considered less successful in containing healthcare cost than public integrated 
systems, mainly because payment of providers is ex-post (Docteur and Oxley, 2003). This is 
confirmed by our finding. None of the other institutional variables are significant drivers of 
healthcare expenditures. This could be due to difficulties of measuring health system 
characteristics in binary variables, and also because there is relatively little change in such 
characteristics over time, and identification has mainly to rely on cross country variation.   
There are a few determinants that nearly reach robustness and statistical significance 
(see figure 1). These are choice of hospital, GP or specialist, road traffic accidents and alcohol 
consumption, and at lower levels of significance, R&D expenditures and insurance coverage. 
Apart from those, sign certainty and fraction significant are low for the remaining determinants. 
Results from fixed effects and CF models are very similar, although four determinants are 
robust according to CF but not FE models, and one robust according to FE but not CF model. 
 
6. Conclusions 
Empirical models of healthcare expenditure growth are affected by at least three 
problems: unobserved heterogeneity in the effect of common shocks across countries, high 
model uncertainty, and missing data. These problems may lead to bias in the estimates of the 
impact of observable cost drivers, and could be partly responsible for the relative wide 
variations in results that have been found in the literature. Objective of our study is to address 
these problems by applying novel econometric methods that have been developed in the 
empirical economic growth literature. The innovative contributions of our study to the analysis 
of HCE growth are, first, to adopt panel data models with a multifactor error structure (Pesaran, 
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2006, Bai, 2009) that allows for variations in the impact of common shocks on HCE growth 
across countries; second, to apply Bayesian model averaging methods (Koop et al., 2007) that 
address model uncertainty and identify important drivers of healthcare expenditure growth; 
third, to use multiple imputation techniques (Rubin, 1987) that incorporate the uncertainty 
surrounding the imputation into final model estimates. We compare our results with a standard 
fixed effects model of HCE growth, and find that estimates are very similar, at least for the 
most robust determinants. This lets us conclude that despite the supremacy of CF models on 
theoretical grounds, in practical application a standard FE model may be perfectly adequate. 
Our analysis has limitations. For many of our results it would be erroneous to infer a direct 
causal relation between a change in the determinant and impact on HCE growth. Some 
determinants may act as proxies for others that are not included in the models, or the 
relationship is highly complex and influenced by other factors. Our data is affected by 
unobserved variables and missing data. Although the OECD Health Statistics is the preferred 
dataset for analysis of HCE growth, some important drivers, in particular institutional variables, 
are poorly represented. Our results are based on historical trends over the past 32 years, and 
may not apply to the coming 32 years.   
Despite the limitations, we can derive some conclusions. A greater reliance on private 
and social insurance, as opposed to public financing, seems to dampen growth. Competitive 
pressures in insurance markets seem to be associated with greater efficiency. Tackling the costs 
of pharmaceuticals, by regulation of the pharmaceuticals and devices markets, is another 
promising policy according to our results. Similarly, slimming health administration is 
predicted to curtail growth. Organisational reforms of the healthcare system should be directed 
to increase efficiency of the management of healthcare provision; further research is necessary 
to establish at what managerial level greatest efficiency gains can be expected. We further find 
that substitution of inpatient with outpatient care can reduce HCE growth, a policy that has 
been fostered by most countries in our study. Characteristics of the healthcare system and 
health indicators show weak associations with HCE growth, but it is important to keep in mind 
that these factors may still have an association with the level of expenditures.  Overall, we hope 
that our results provide robust evidence to policy makers on the drivers that are most strongly 
associated with the growth in HCE, and will be used to inform effective policies in OECD 
countries.   
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Table 1: List of OECD countries and years included in the study 
 
Country Year 
Australia 1981-2010 
Austria 1981-2011 
Belgium 1981-2011 
Canada 1981-2012 
Chile 1996-2012 
Czech Republic 1991-2011 
Denmark 1981-2011 
Estonia 2000-2011 
Finland 1981-2012 
France 1991-2011 
Germany 1981-1990, 1993-2011 
Greece 1988-2011 
Hungary 1992-2012 
Iceland 1981-2012 
Ireland 1981-2011 
Israel 1981-2011 
Italy 1989-2012 
Japan 1981-2010 
Korea 1981-2012 
Luxembourg 1996-2011 
Mexico 1991-2010 
Netherlands 1981-2011 
New Zealand 1981-2011 
Norway 1981-2012 
Poland 1991-2011 
Portugal 1981-2011 
Slovak Republic 1998-2011 
Slovenia 1996-2012 
Spain 1981-2011 
Sweden 1981-2011 
Switzerland 1981-2012 
Turkey 1981-2008 
United Kingdom 1981-2011 
United States 1981-2011 
 
Note: Country-years with missing values on healthcare expenditure growth are excluded from analysis. 
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Table 2: Descriptive Statistics for the Original Data Set 
Variable Description Obs Mean Std. Dev. Min Max 
lnhce Total expenditure on health (per capita, NCU at 2005 GDP price level) 909 3.37 4.82 -28.33 29.42 
lnacc Road traffic accidents (injured per million population) 839 -0.93 7.91 -76.37 30.17 
lnalc Alcohol consumption (ltr per capita, ages 15+) 846 -0.36 5.12 -32.54 30.01 
lnbsi Acute care beds (per 1,000 population) 628 -1.63 3.70 -29.09 34.80 
pbirt Births, live (per 1,000 population) 889 -0.11 0.42 -3.10 3.70 
pcanm Neoplasms, deaths (per 100,000 population) 831 -1.39 5.36 -26.20 27.90 
pcove Insurance coverage (% of population) 752 0.24 1.90 -5.10 36.40 
pfpr Labor force participation rate, female (% of female population ages 15+) 552 450.90 89.18 100.87 666.70 
lngdp Gross domestic product (per capita, US$ at 2005 PPP) 909 4.83 3.53 -10.37 19.38 
lnger R&D expenditures (million of US$ at 2005 PPP) 592 5.04 7.39 -35.35 49.68 
pgp1 Public coverage of health care (% of total population) 808 0.27 1.93 -5.10 37.40 
lngp Generalist medical practitioners (per 1,000 population) 457 0.01 0.06 -0.53 0.55 
pgsh Expenditure of general government, total (% of GDP) 645 0.01 2.35 -18.42 17.34 
phemp Health and social employment (% total employment) 495 0.12 0.47 -2.51 5.49 
lnhospc General hospitals (per 1,000 population) 525 -1.74 5.37 -39.01 36.85 
lninp Inpatient care discharges, all hospitals (per 100,000 population) 610 0.43 3.43 -27.66 16.55 
lnlos Length of stay in hospital, all causes (average days) 504 -1.64 4.74 -33.85 21.67 
lnmt Life-years lost (all causes per 100,000 population, 0-69 years) 816 -2.49 3.19 -21.98 18.71 
lnpha Pharmaceutical sales (per capita, US$ at 2005 PPP) 456 5.60 6.59 -22.99 32.99 
lndoc Physicians (per 1,000 population) 579 1.97 6.06 -34.79 65.68 
lnins Insurance premiums, private and social (per capita, US$ at 2005 PPP) 517 4.12 7.47 -54.36 34.69 
ppins Private insurance expenditure (% total health expenditure) 577 0.07 0.57 -7.76 3.17 
ppop6 Population above 65 years (% total population) 899 0.15 0.17 -0.70 1.00 
ppop8 Population above 80 years (% total population) 876 0.07 0.08 -0.50 0.40 
ppuhe Health expenditure, public (% total health expenditure) 762 -0.03 2.04 -16.10 15.10 
pedx Public spending on education, total (% of government expenditure) 515 0.04 0.71 -4.61 3.43 
psss Social insurance expenditure (% total health expenditure) 626 -0.04 1.86 -23.10 10.72 
lnta Health administration, expenditures (per capita, NCU at 2005 GDP price level) 477 4.25 22.27 -150.41 248.49 
ptexm Inpatient expenditures (% total health expenditure) 594 -0.41 2.44 -22.00 9.70 
lntob Tobacco consumption (grams per capita, age 15+) 624 -2.02 7.04 -64.34 53.54 
lndp Population density (per km2) 909 0.67 0.68 -3.96 6.01 
punem Unemployment rate, total (% civilian labour force) 675 0.09 1.25 -4.45 8.27 
lnle Life expectancy at age 65 (total) 885 0.85 1.22 -4.85 7.87 
mic Middle income country 909 0.18 0.39 0.00 1.00 
capit Capitation remuneration (primary care) 909 0.14 0.34 0.00 1.00 
caseh Fee-for-service (in-patient care) 909 0.17 0.38 0.00 1.00 
copay Copayment for GP or hospital 909 0.72 0.45 0.00 1.00 
ffsa Fee-for-service (primary care) 909 0.29 0.46 0.00 1.00 
free Choice of hospital, GP or specialist 909 0.97 0.18 0.00 1.00 
gatek Gatekeeper GPs 909 0.52 0.50 0.00 1.00 
globu Global Budgets (in-patient care) 909 0.33 0.47 0.00 1.00 
hcspc Public contract healthcare system 909 0.53 0.50 0.00 1.00 
mixgp Mix of capitation and fee-for-service (primary care) 909 0.30 0.46 0.00 1.00 
ws Salary renumeration (primary care) 909 0.20 0.40 0.00 1.00 
Notes: Summary statistics are calculated across countries and years; level variables are converted into growth rates and prefixed “ln”; 
proportion/share variables are first differenced and prefixed “p”. 
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Table 3.Descriptive Statistics for Two Imputed Data Sets 
 1st Imputed data set 50th Imputed data set 
Variable Mean Std. Dev. Min Max Mean Std. Dev. Min Max 
lnacc -1.26 9.02 -76.37 30.17 -1.00 8.65 -76.37 30.17 
lnalc -0.37 5.05 -32.54 30.01 -0.34 5.10 -32.54 30.01 
lnbsi -1.32 4.05 -29.09 34.80 -1.33 4.51 -29.09 34.80 
pbirt -0.12 0.42 -3.10 3.70 -0.11 0.43 -3.10 3.70 
pcanm -1.15 5.93 -26.20 27.90 -1.31 5.38 -26.20 27.90 
pcove 0.25 1.82 -5.10 36.40 0.27 1.91 -5.10 36.40 
pfpr 454.78 92.36 100.87 666.70 454.41 89.99 100.87 666.70 
lngdp 4.83 3.53 -10.37 19.38 4.83 3.53 -10.37 19.38 
lnger 6.03 8.50 -35.35 49.68 4.99 8.98 -35.35 49.68 
pgp1 0.32 1.92 -5.10 37.40 0.32 1.95 -5.10 37.40 
lngp 0.02 0.08 -0.53 0.55 0.01 0.08 -0.53 0.55 
pgsh -0.03 3.12 -18.42 17.34 -0.09 2.72 -18.42 17.34 
phemp 0.15 0.60 -2.51 5.49 0.14 0.58 -2.51 5.49 
lnhospc -2.27 6.58 -39.01 36.85 -1.73 5.53 -39.01 36.85 
lninp 0.40 3.67 -27.66 16.55 0.92 4.69 -27.66 16.55 
lnlos -2.52 5.06 -33.85 21.67 -2.23 5.24 -33.85 21.67 
lnmt -2.44 3.24 -21.98 18.71 -2.47 3.22 -21.98 18.71 
lnpha 7.00 7.62 -22.99 32.99 6.72 6.59 -22.99 32.99 
lndoc 1.77 6.80 -34.79 65.68 1.91 6.34 -34.79 65.68 
lnins 4.41 9.65 -54.36 34.69 4.16 8.75 -54.36 34.69 
ppins 0.05 0.64 -7.76 3.17 0.07 0.61 -7.76 3.17 
ppop6 0.15 0.17 -0.70 1.00 0.15 0.17 -0.70 1.00 
ppop8 0.07 0.08 -0.50 0.40 0.07 0.08 -0.50 0.40 
ppuhe -0.04 1.96 -16.10 15.10 0.01 2.02 -16.10 15.10 
pedx 0.08 0.81 -4.61 3.43 0.08 0.86 -4.61 3.43 
psss -0.05 2.17 -23.10 10.72 -0.10 1.97 -23.10 10.72 
lnta -0.61 32.85 -150.41 248.49 0.64 31.03 -150.41 248.49 
ptexm -0.51 2.92 -22.00 9.70 -0.25 2.83 -22.00 9.70 
lntob 0.55 11.58 -64.34 53.54 -2.71 7.35 -64.34 53.54 
lndp 0.67 0.68 -3.96 6.01 0.67 0.68 -3.96 6.01 
punem 0.04 1.22 -4.45 8.27 0.14 1.23 -4.45 8.27 
lnle 0.83 1.31 -9.33 7.87 0.82 1.30 -6.57 7.87 
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Table 4. Bayesian Model Averaging Estimation Results for Robust Determinants of Healthcare Expenditure Growth 
    A.     Common factor models B.    Fixed effect models 
Determinant  
Impact on 
HCE growth 
(SD change) 
Posterior 
Mean 
Posterior 
Standard 
Deviation 
Sign 
Certainty 
Probability2 
Fraction of 
Regressions 
with |tstat|>2 
Posterior 
Mean 
Posterior 
Standard 
Deviation 
Sign 
Certainty 
Probability 
Fraction of 
Regressions 
with 
|tstat|>2 
Insurance premiums, private and social (per 
capita, US$ at 2005 PPP) 
lnins 1.31 0.2220***3 0.0556 1 1 0.2143*** 0.057 1 1 
Social insurance expenditure (% total health 
expenditure) 
psss -0.96 -0.8086*** 0.1746 1 1 -0.8320*** 0.1793 1 1 
Pharmaceutical sales (per capita, US$ at 2005 
PPP) 
lnpha 0.83 0.1537*** 0.0408 0.9997 0.9987 0.1449*** 0.0413 0.9993 0.9958 
Unemployment rate, total (% civilian labour 
force) 
punem -0.81 -0.7289*** 0.1779 0.9998 0.9995 -0.7932*** 0.2 0.9998 1 
Gross domestic product (per capita, US$ at 
2005 PPP) 
lngdp 0.77 0.2329*** 0.0814 0.9955 0.971 0.2589*** 0.0794 0.9978 0.9767 
Private insurance expenditure (% total health 
expenditure) 
ppins -0.51 -1.3837*** 0.6674 0.9982 0.9987 -1.3412*** 0.6805 0.9971 0.9998 
Public spending on education, total (% of 
government expenditure) 
pedx 0.46 0.7309** 0.3136 0.9883 0.8765 0.7337** 0.3545 0.9782 0.7834 
Population above 65 years (% total 
population) 
ppop6 0.40 3.0026** 1.1341 0.9932 0.9413 2.4764* 1.229 0.9746 0.6468 
Health administration, expenditures (per 
capita, NCU at 2005 GDP price level) 
lnta 0.35 0.0196*** 0.0071 0.9953 0.9884 0.0201** 0.0085 0.9888 0.9779 
Inpatient care discharges, all hospitals (per 
100,000 population) 
lninp 0.35 0.1324** 0.0566 0.9891 0.9202 0.1481** 0.0656 0.9858 0.9151 
Expenditure of general government, total (% 
of GDP) 
pgsh 0.34 0.1626* 0.0916 0.9658 0.5331 0.2032* 0.1068 0.9724 0.4769 
Inpatient expenditures (% total health 
expenditure) 
ptexm -0.34 -0.1617* 0.0802 0.9719 0.7905 - - - - 
Acute care beds (per 1,000 population) lnbsi 0.28 0.0954* 0.0507 0.9659 0.5511 0.1318** 0.0634 0.9779 0.7393 
Tobacco consumption (grams per capita, age 
15+) 
lntob 0.25 0.0408* 0.0225 0.9619 0.4578 - - - - 
Capitation remuneration (primary care) capit 0.22 1.9228* 1.0495 0.97 0.872 - - - - 
Public contract healthcare system hcspc 0.05 2.2973** 1.0279 0.9815 0.8957 - - - - 
Salary remuneration (primary care) ws - - - - - -1.9581* 1.0934 0.9601 0.5446 
Notes: 1Impact is measured as the % change in HCE growth rate associated with a one SD % change in the determinant; SD is calculated across years within country. 
2Posterior probability that a variable has the same sign as its posterior mean conditional on inclusion 
3*** indicates that variable has robust impact on health expenditure growth at 1% significant level, ** for 5%, and * for 10%.   
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Figure 1: Non-robust Determinants of Healthcare Expenditure Growth 
 
Note: Figure displays only determinants with sign certainty <0.95 and >0.05; sign certainty is increasing towards the right (for positive determinant) and left (for negative determinants); significance is increasing 
towards the top of the figure.
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Appendix I Bayesian Model Averaging 
Most studies that use Bayesian Model Averaging (BMA) to identify determinants of economic growth 
at country level are based on cross-sectional models.5  Let  y X   represent a generic regression model 
of health care expenditure growth ( y ) on a set of growth determinants ( X ). Given the large number of 
potential growth determinants, there potentially exist an enormous amount of empirical models when the 
empirical researcher seeks to explore different combination of determinants.  Suppose we have K potential 
determinants, we then would have a maximum of 2K possible combinations of regressors, i.e. 2K  different 
models to estimate. Let rM  ( 1,2,...,2
Kr  ) denote the rth model under consideration, then rM  depends on 
a set of growth determinants, rX , and their corresponding coefficients 
r . By Bayes’ rule in densities, the 
posterior density for 
r  under model rM  is written as  
                                            
( | , ) ( | )
( | , ) ,
( | )
r r
r r r
r
r
f M p M
p M
f M

y
y
y
 
                                        (A-1) 
where ( | )
r
rp M  is the prior density of 
r ; ( | , )r rf My   denotes likelihood of y  given 
r  under model 
rM ; and ( | )rf My  is the prior density of y . 
Using Bayes’ rule, the posterior probability, ( | )rp M y for 1,2,...,2
Kr  , can be obtained as  
                                                     
( | ) ( )
( | ) ,
( )
r r
r
f M p M
p M
f

y
y
y
                                                   (A-2) 
which can be used to assess the degree of support for rM . The prior density of rM , i.e. ( )rp M , measures 
how likely we believe rM  to be the correct model concerning the relative likelihood of all possible models 
before considering the data.  ( | )rf My  is the marginal likelihood and is calculated by integrating both sides 
of Equation (A-1) with respect to 
r . Use the fact that ( | , ) 1r rrp M d  y  , we get  
                                          ( | ) ( | , ) ( | ) .r r rr r rf M f M p M d y y                                             (A-3) 
 Let  be a vector of parameters that has a common interpretation in all models, i.e.  is function of 
r  for each 1,2,...,2
Kr  . According to the rules of probabilities, we can calculate the posterior density of 
the parameters for all the models under consideration as  
                                                          
5 To the best knowledge of authors, the only one exception is Moral-Benito MORAL-BENITO, E. 2012. Determinants of 
economic growth: a Bayesian panel data approach. Review of Economics and Statistics, 94, 566-579.. 
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Follow Raftery (1995) and Sala-i-Martin et al. (2004), the posterior probability of model rM  is  
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where NT is the number of observations, 
rk  is the number of regressors included in model rM , and rSSE  is 
the sum of squared residuals from the rth regression model of rM .  
 Regarding the specification of prior probabilities attached to different models, , a common 
practice is to assign equal prior probability to each model.  This however has troubling implications when the 
number of models under consideration is large. In particular it implies a very strong prior belief that the 
number of regressors included in the true model is very large, with expected model size equal to . Instead 
of choosing prior probabilities for different models, we specify a prior mean model size, .  Each variable 
has the same prior probability, i.e. , of being included, and the probability is independent of the inclusion 
of any other variables. In our empirical analysis, we choose but also compare results to 6. We find 
that different prior assumptions about the model size have no practical impact on the results.  
 
  
                                                          
6 Results are available upon request. 
( )rp M
2K
k
k K
7k  5k 
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Appendix II Multiple Imputation 
For each imputed data-set, we estimate the common factor model in different specifications. Let  
represent the estimated parameters from common factor model with specification  ( ) by using 
the m-th (  ) imputed data set. Let  be the completed-data point 
estimates and variance-covariance estimates of  from M imputed datasets. For , the MI point estimation 
of is given as 
,                                                   (A-6) 
and the MI variance-covariance estimate is  
.               (A-7) 
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